Peyronie’s disease: pharmacological treatments and limitations

References

• Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194(3):745–753.
   PubMed Web of Science ®Google Scholar
• Androutsos G. [Francois Gigot de La Peyronie(1678-1747), benefactor of surgery and supporter of the fusion of medicine and surgery, and the disease that bears his name]. Prog Urol. 2002;12(3):527–533.
   PubMed Web of Science ®Google Scholar
• Musitelli S, Bossi M, Jallous J. A brief historical survey of “Peyronie’s disease”. J Sex Med. 2008;5(7):1737–1746.
   PubMed Web of Science ®Google Scholar
• Arafa M, Eid H, El-Badry A, et al. The prevalence of Peyronie’s disease in diabetic patients with erectile dysfunction. Int J Impot Res. 2007;19(2):213–217.
   PubMed Web of Science ®Google Scholar
• Dibenedetti DB, Nguyen D, Zografos L, et al. A population-based study of peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;282503:2011.
   Google Scholar
• Moreland RB, Nehra A. Pathophysiology of Peyronie’s disease. Internal J Impotence Res. 2002;14:406–410.
   PubMed Web of Science ®Google Scholar
• Somers KD, Dawson DM. Fibrin deposition in Peyronie’s disease plaque. J Urol. 1997;157:311–315.
   PubMed Web of Science ®Google Scholar
• Border WA, Ruoslahti E. Transforming growth factor-b in disease: the dark side of tissue repair. J Clin Inv. 1992;90:1–7.
   PubMed Web of Science ®Google Scholar
• Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie’s plaque fibroblasts. J Urol. 2008;179(6):2447–2455.
   PubMed Web of Science ®Google Scholar
• Kelly RB. Pathways of protein secretion in eukaryotes. Science. 1985;230(4721):25–32.
   PubMed Web of Science ®Google Scholar
• Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151(6):1522–1524.
   PubMed Web of Science ®Google Scholar
• Levine LA, Goldman KE, Greenfield J. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol. 2002;168(2):621.
   PubMed Web of Science ®Google Scholar
• Shirazi M, Haghpanah AR, Badiee M, et al. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41(3):467–471.
   PubMed Web of Science ®Google Scholar
• Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve peyronie’s disease plaque: a long-term single-blind study. Urology. 1998;51(4):620–626.
   PubMed Web of Science ®Google Scholar
• Bennett NE, Mulhall JP. Intralesional verapamil prevents the progression of peyronie’s disease. J Urol. 2007;69(6):1181–1184.
   Google Scholar
• Levine LA. Treatment of Peyronie’s disease with intralesional verapamil injection. J Urol. 1997;158(4):1395–1399.
   PubMed Web of Science ®Google Scholar
• Favilla V, Russo GI, Privitera S, et al. Combination of intralesional verapamil and oral antioxidants for Peyronie’s disease: a prospective, randomized controlled study. Andrologia. 2014;46:936–942.
   PubMed Web of Science ®Google Scholar
• Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991;25:89–94.
   PubMed Web of Science ®Google Scholar
• Wegner HE, Andreson R, Knipsel HH, et al. Treatment of Peyronie’s disease with local interferon-alpha 2b. Eur Urol. 1995;28(3):236–240.
   PubMed Web of Science ®Google Scholar
• Kendirci M, Usta MF, Matern RV, et al. The impact of intralesional interferon alpha-2b injection therapy on penile hemodyanmics in men with Peyronie’s disease. J Sex Med. 2005;2(5):709–715.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2b for minimally invasive treatment for peyronie’s disease. J Urol. 2006;176:394–398.
   PubMed Web of Science ®Google Scholar
• Trost LW, Ates E, Powers M, et al. Outcomes of intralesional interferon-α2B for the treatment of Peyronie’s disease. J Urol. 2013;190:2194–2199.
   PubMed Web of Science ®Google Scholar
• Stewart CA, Yafi FA, Knoedler M, et al. Intralesional injection of interferon-alpha2b improves penile curvature in men with peyronie’s disease independent of plaque location. J Urol. 2015;194:1704–1707.
   PubMed Web of Science ®Google Scholar
• Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie’s disease experimental studies. Urol Res. 1982;10:135–140.
   PubMed Web of Science ®Google Scholar
• Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie’s disease. J Urol. 1985;134:280–283.
   PubMed Web of Science ®Google Scholar
• Gelbard MK, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized placebo controlled phase 3 studies. J Urol. 2013;190:199–207.
   PubMed Web of Science ®Google Scholar
• Lipshultz LI, Goldstein I, Seftel AD, et al. Clinical efficacy of collagenase clostridium histolyticum in the treatment of peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015;116(4):650–656.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Nguyen HM, Alzweri L, et al. Intralesional collagenase clostridium histolyticum causes meaningful improvement in men with peyronie’s disease: results of a multi-institutional analysis. J Urol. 2019;201(4):777–782.
   PubMed Web of Science ®Google Scholar
• Nguyen HMT, Anaissie J, DeLay KJ, et al. Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute-phase peyronie’s disease. J Sex Med. 2017;14(10):1220–1225.
   PubMed Web of Science ®Google Scholar
• Liu T, Shindel A, Lin G, et al. Cellular signaling pathways modulated by low-intensity extracorporeal shock wave therapy. Int J Impot Res. 2019;31(3):170–176.
   PubMed Web of Science ®Google Scholar
• Wang CJ. Extracorporeal shockwave therapy in musculoskeletal disorders. J Orthop Surg Res. 2012;7:11.
   PubMed Web of Science ®Google Scholar
• Rassweiler JJ, Renner C, Chaussy C, et al. Treatment of renal stones by extracorporeal shockwave lithotripsy: an update. Eur Urol. 2001;39:187–199.
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Eardley I, Giuliano F, et al. EAU guidelines on penile curvature. Eur Urol. 2012;62:543–552.
   PubMed Web of Science ®Google Scholar
• Bellorofonte C, Ruoppolo M, Tura M, et al. [Possibility of using the piezoelectric lithotriptor in the treatment of severe cavernous fibrosis]. Arch Ital Urol Nefrol Androl. 1989;61:417–422.
   PubMedGoogle Scholar
• Abdel-Salam Y, Budair Z, Renner C, et al. Treatment of Peyronie’s disease by extracorporeal shockwave therapy: evaluation of our preliminary results. J Endourol. 1999;13:549–552.
   PubMed Web of Science ®Google Scholar
• Palmieri A, Imbimbo C, Longo N, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Eur Urol. 2009;56:363–369.
   PubMed Web of Science ®Google Scholar
• Chitale S, Morsey M, Swift L, et al. Limited shock wave therapy vs sham treatment in men with Peyronie’s disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010;106:1352–1356.
   PubMed Web of Science ®Google Scholar
• Hatzichristodoulou MC, Meisner C, Gschwend JE, et al. Extracorporeal shock wave therapy in Peyronie’s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10:2815–2821.
   PubMed Web of Science ®Google Scholar
• Gao LQS, Qian S, Tang Z, et al. A meta-analysis of extracorporeal shock wave therapy for Peyronie’s disease. Int J Impot Res. 2006;28:161–166.
   Google Scholar
• Bekos A, Arvaniti M, Hatzimouratidis K, et al. The natural history of Peyronie’s disease: an ultrasonography-based study. Eur Urol. 2008;53(3):644–650.
   PubMed Web of Science ®Google Scholar
• Bella AJ, Lee JC, Grober ED, et al. Canadian Urological Association guideline for Peyronie’s disease and congenital penile curvature. Can Urol Assoc J. 2018;12(E197–209):2018.
   Google Scholar
• Scroppo FI, Mancini M, Maggi M, et al. Can an external penis stretcher reduce Peyronie’s penile curvature? Int J Impot Res. 2001;13(Suppl. 4): S21.
   Google Scholar
• Lin H, Liu C, Wang R. Effect of penile traction and vacuum erectile device for peyronie’s disease in an animal model. J Sex Med. 2017;14:1270–1276.
   PubMed Web of Science ®Google Scholar
• Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med. 2008;5(6):1468–1473.
   PubMed Web of Science ®Google Scholar
• Martínez‐Salamanca JI, Egui A, Moncada I, et al. Acute phase peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med. 2014;11(2):506–515.
   PubMed Web of Science ®Google Scholar
• Moncada KP, Krishnappa P, Romero J, et al. Penile traction therapy with the new device ‘Penimaster PRO’ is effective and safe in the stable phase of peyronie’s disease: a controlled multicentre study. BJU Int. 2019;123(4):694–702.
   PubMed Web of Science ®Google Scholar
• Ziegelmann M, Savage J, Toussi A, et al. Outcomes of a novel penile traction device in men with peyronie’s disease: a randomized, single-blind, controlled trial. J Urol. 2019;202(3):599–610.
   PubMed Web of Science ®Google Scholar
• Cowper MG, Burkett CB, Le TV, et al. Penile stretching as a treatment for Peyronie’s disease: a review. Sex Med Rev. 2019;7(3):508–515.
   PubMed Web of Science ®Google Scholar
• Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for peyronie’s disease. J Sex Med. 2011;9(1):288–295.
   PubMed Web of Science ®Google Scholar
• Martin DJ, Badwan K, Parker M, et al. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2002;168(6):2483–2485.
   PubMed Web of Science ®Google Scholar
• Lee RC. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res. 1990;49(5):463–466.
   PubMed Web of Science ®Google Scholar
• Fitch WP, Easterling WJ, Talbert RL, et al. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of peyronie’s disease–a placebo-controlled pilot study. J Sex Med. 2007;4(2):477–484.
   PubMed Web of Science ®Google Scholar
• Levine LA. Comment on ‘Topical verapamil HCL, topical trifluoroperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease–a placebo-controlled pilot study’. J Sex Med. 2007;4:1081–1082.
   PubMed Web of Science ®Google Scholar
• Montorsi F, Salonia A, Guazzoni G, et al. Transdermal electromotive multi-drug administration for Peyronie’s disease: preliminary results. J Androl. 2000;21:85–90.
   PubMed Web of Science ®Google Scholar
• Levine LA, Estrada CR, Shou W, et al. Tunica albuginea tissue analysis after electromotive drug administration. J Urol. 2003;169(5):1775–1778.
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for peyronie’s disease. J Urol. 2004;171(4):1605.
   PubMed Web of Science ®Google Scholar
• Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for peyronie’s disease: a double-blind, placebo controlled trial. J Urol. 2007;177(3):972–975.
   PubMed Web of Science ®Google Scholar
• Mehrsai AR, Namdari F, Salavati A, et al. Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie’s disease. Andrology. 2013;1:129–132.
   PubMed Web of Science ®Google Scholar
• Riedl CR, Plas E, Vorauer K, et al. Pilot study on liposomal recombinant human superoxide dismutase for the treatment of peyronie’s disease. Eur Urol. 2001;40(3):343–349.
   PubMed Web of Science ®Google Scholar
• Riedl CR, Sternig P, Gallé G, et al. Liposomal recombinant human superoxide dismutase for the treatment of peyronie’s disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol. 2005;48(4):656–661.
   PubMed Web of Science ®Google Scholar
• Twidwell JL. Topical treatment for acute phase peyronie’s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. Int J Impot Res. 2016;28(2):41–45.
   PubMed Web of Science ®Google Scholar
• Smith JF, Shindel AW, Huang YC, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease. Asian J Androl. 2011;13:322–325.
   PubMed Web of Science ®Google Scholar
• McCarty MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses. 1997;52:465–477.
   Web of Science ®Google Scholar
• Noel C, Copin MC, Hazzan M, et al. Immunomodulatory effect of pentoxifylline during human allograft rejection: involvement of tumor necrosis factor-alpha and adhesion molecules. Transplantation. 2000;69:1102–1107.
   PubMed Web of Science ®Google Scholar
• Tittelbach J, Graefe T, Wollina U. Painful ulcers in calciphylaxis - combined treatment with maggot therapy and oral pentoxyfillin. J Dermatolog Treat. 2001;12:211–214.
   PubMed Web of Science ®Google Scholar
• Pavan A, Krishna B. Pentoxifylline. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. [cited 2021 Feb 28]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559096/
   Google Scholar
• Safarinejad MR, Asgari MA, Hosseini SY, et al. Retraction statement: a double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease. BJU Int. 2015;115:E10.
   PubMed Web of Science ®Google Scholar
• Paulis G, Brancato T, D’Ascenzo R, et al. Efficacy of vitamin E in the conservative treatment of Peyronie’s disease: legend or reality? A controlled study of 70 cases. Andrology. 2013;1:120–128.
   PubMed Web of Science ®Google Scholar
• Gallo LS, Sarnacchiaro P. Ten-year experience with multimodal treatment for acute phase Peyronie’s disease: a real life clinical report. Actas Urol ESP. 2019;43:182–189.
   PubMed Web of Science ®Google Scholar
• Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47:530–535.
   PubMed Web of Science ®Google Scholar
• El-Sakka AI, Bakircioglu ME, Bhatnagar RS, et al. The effects of colchicine on a Peyronie’s-like condition in an animal model. J Urol. 1999;161:1980–1983.
   PubMed Web of Science ®Google Scholar
• Akkus E, Carrier S, Rehman J, et al. Is colchicine effective in Peyronie’s disease? A pilot study. Urology. 1994;44:291–295.
   PubMed Web of Science ®Google Scholar
• Kadioglu A, Tefekli A, Koksal T, et al. Treatment of Peyronie’s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res. 2000;12:169–175.
   PubMed Web of Science ®Google Scholar
• Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16:238–243.
   PubMed Web of Science ®Google Scholar
• Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int. 2003;91:522–524.
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Hosseini SY, Kolahi AA, et al. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic peyronie’s disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178:1398–1403.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Hisasue SI, Kato R, et al. Outcome analysis for conservative management of Peyronie’s disease. Int J Urol. 2006;13:244–247.
   PubMed Web of Science ®Google Scholar
• Lindsay MB, Schain DM, Grambsch P, et al. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol. 1991;146:1007–1009.
   PubMed Web of Science ®Google Scholar
• Ralph DJ, Mirakian R, Pryor JP, et al. The immunological features of Peyronie’s disease. J Urol. 1996;155:159–162.
   PubMed Web of Science ®Google Scholar
• Colletta AA, Wakefield LM, Howell FV, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer. 1990;62:405–409.
   PubMed Web of Science ®Google Scholar
• Ralph DJ, Brooks MD, Bottazzo GF, et al. The treatment of Peyronie’s disease with tamoxifen. Br J Urol. 1992;70:648–651.
   PubMedGoogle Scholar
• Teloken C, Rhoden EL, Grazziotin TM, et al. Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol. 1999;162:2003–2005.
   PubMed Web of Science ®Google Scholar
• Vacante F, Senesi P, Montesano A, et al. L-carnitine: an antioxidant remedy for the survival of cardiomyocytes under hyperglycemic condition. J UDiabetes Res. 2018;4028297:2018.
   Google Scholar
• Calò L, Pagnin E, Davis PA, et al. Antioxidant effect of l-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol. 2006;107:54–60.
   PubMed Web of Science ®Google Scholar
• Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU Int. 2001;88:3–7.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie’s disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol. 2010;7:215–221.
   PubMed Web of Science ®Google Scholar
• Valente EG, Vernet D, Ferrini MG, et al. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9:229–244.
   PubMed Web of Science ®Google Scholar
• Chung E, DeYoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8:1472–1477.
   PubMed Web of Science ®Google Scholar
• Palmieri A, Imbimbo C, Creta M, et al. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;353:190–195.
   Google Scholar
• Gokce A, Abd Elmageed ZY, Lasker GF, et al. Intratunical injection of genetically modified adipose tissue-derived stem cells with human interferon alpha-2b for treatment of erectile dysfunction in a rat model of tunica albugineal fibrosis. J Sex Med. 2015;12(7):1533–1544.
   PubMed Web of Science ®Google Scholar
• Dolmans GH, Werker PM, De Jong IJ, et al. WNT2 locus is involved in genetic susceptibility of peyronie’s disease. J Sex Med. 2009;9:1430–1434.
   Google Scholar
• Moussa M, Chakra MA, Moussa Y. Advances in stem cell therapy for treatment of Peyronie’s disease. Intractable Rare Dis Res. 2020;9(1):10–13.
   PubMed Web of Science ®Google Scholar
• Ziegelmann MJ, Trost LW, Russo GI, et al. Peyronie’s disease intervention studies: an exploration of modern-era challenges in study design and evaluating treatment outcomes. J Sex Med. 2020;17(3):364–377.
   PubMed Web of Science ®Google Scholar